Research programme: obesity therapy - Millennium Pharmaceuticals
Latest Information Update: 31 May 2006
At a glance
- Originator Millennium Pharmaceuticals
- Class
- Mechanism of Action Fatty acid transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 31 Dec 2005 No development reported - Preclinical for Obesity in USA (unspecified route)
- 14 Nov 2001 New profile
- 14 Nov 2001 Preclinical development for Obesity in USA (Unknown route)